Has acalatinib been officially launched in the Chinese market?

Acalabrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor mainly used to treat hematological malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia. In recent years, acotinib has gradually gained recognition worldwide due to its better efficacy and lower side effects. In the Chinese market, acotinib has been officially launched, bringing more treatment options to patients.

At present, acotinib has been included in China's medical insurance catalog, and patients can purchase and use it through formal domestic channels. This is undoubtedly a great boon to many patients who require long-term treatment and reduces the financial burden. However, because acotinib is an innovative drug, its price in China is relatively high. The general price is more than 20,000 yuan per box. The specific price and medical insurance reimbursement ratio may vary depending on the region and hospital.

In contrast, there are some more affordable generic versions of acotinib on the foreign market, especially the Lao version, which sells for about more than 3,000 yuan, which is much lower than the domestic original drug. It is worth noting that the ingredients and efficacy of these generic drugs are basically the same as those of domestic original drugs, making them the choice of some patients to purchase them through overseas channels.

In short, acotinib has been officially launched in the Chinese market and included in medical insurance, providing patients with a formal and convenient treatment path. Although the price is higher, medical insurance support and diversified purchasing channels have alleviated patients' financial pressure to a certain extent. When using acotinib, patients are advised to consult the local hospital pharmacy to learn about the latest medical insurance policies and price information to ensure rational use of the drug.

Reference materials:https://www.drugs.com